February 15, 2015Seminars in Thrombosis and Hemostasis
Comparative Efficacy and Safety of the Non–Vitamin K Antagonist Oral Anticoagulants for Patients with Nonvalvular Atrial Fibrillation
Key result
Non-vitamin K antagonist oral anticoagulants are at least as efficacious and safe as vitamin K antagonists for stroke prevention in patients with nonvalvular atrial fibrillation.
Why the study?
Do non-vitamin K antagonist oral anticoagulants (NOACs) provide comparable efficacy and safety to vitamin K antagonists for stroke prevention in patients with nonvalvular atrial fibrillation?
Population
Patients with nonvalvular atrial fibrillation (NVAF)
Comparison
Non-vitamin K antagonist oral anticoagulants… vs Vitamin K antagonists (VKAs) such as warfarin
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Supports NOAC use over VKAs in nonvalvular AF; leaves open optimal selection by individual risk profiles.
Structured PICO
Do non-vitamin K antagonist oral anticoagulants (NOACs) provide comparable efficacy and safety to vitamin K antagonists for stroke prevention in patients with nonvalvular atrial fibrillation?
P
Population
Patients with nonvalvular atrial fibrillation (NVAF)
I
Intervention
Non-vitamin K antagonist oral anticoagulants (NOACs) including dabigatran, rivaroxaban, apixaban, and edoxaban
C
Comparator
Vitamin K antagonists (VKAs) such as warfarin
O
Outcome
Stroke prevention and safety (bleeding risk)
NOACs offer an efficacious and safe alternative to VKAs for stroke prevention in nonvalvular atrial fibrillation, though selection requires individualized assessment of stroke and bleeding risks.
Cite This Study
Senoo et al. (2015) conducted a review in Nonvalvular Atrial Fibrillation. Non-vitamin K antagonist oral anticoagulants (NOACs) vs. Vitamin K antagonists (VKAs) was evaluated on Stroke prevention. Non-vitamin K antagonist oral anticoagulants are at least as efficacious and safe as vitamin K antagonists for stroke prevention in patients with nonvalvular atrial fibrillation.